Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

HealthDay News — For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7% on average, which is lower than the percentages reported ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

In contrast, people in clinical trials lost 14.9% and 20.9% of their body weight on semaglutide or tirzepatide, respectively. Why Don’t Weight Loss Drugs Work As Well Outside of Clinical Trials?